CRLX101 and Paclitaxel Combination Study in Ovarian Cancer Initiated by NewLink Genetics
A clinical trial is underway to evaluate the maximum tolerated dose of CRLX101 in combination with weekly paclitaxel for ovarian cancer patients.
Asset / Drug
Drug and asset intelligence for CRLX101 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.